Compare RPRX & CPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPRX | CPAY |
|---|---|---|
| Founded | 1996 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 20.6B |
| IPO Year | 2020 | 2010 |
| Metric | RPRX | CPAY |
|---|---|---|
| Price | $49.46 | $307.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $51.40 | ★ $382.64 |
| AVG Volume (30 Days) | ★ 2.5M | 458.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 7.59 |
| EPS | 1.78 | ★ 15.03 |
| Revenue | $2,378,193,000.00 | ★ $4,528,403,000.00 |
| Revenue This Year | $38.63 | $18.65 |
| Revenue Next Year | $4.73 | $10.46 |
| P/E Ratio | $28.12 | ★ $20.47 |
| Revenue Growth | 5.06 | ★ 13.93 |
| 52 Week Low | $31.97 | $252.84 |
| 52 Week High | $50.47 | $361.99 |
| Indicator | RPRX | CPAY |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 44.32 |
| Support Level | $35.34 | $303.63 |
| Resistance Level | $50.08 | $316.98 |
| Average True Range (ATR) | 0.87 | 9.70 |
| MACD | -0.06 | -1.83 |
| Stochastic Oscillator | 61.59 | 17.01 |
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.